The P2X1 receptor and platelet function

Purinergic Signalling

Volumn 7, Issue 3, 2011, Pages 341-356

  Mahaut Smith, Martyn P ^a   Jones, Sarah ^a   Evans, Richard J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

ATP; P2X1; Platelets; Shear; Thromboembolism; Thrombosis

Indexed keywords

EID: 80052371821     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-011-9224-0     Document Type: Article

References (161)

1. 1 receptor. Mol Pharmacol 54: 1118-1123.
2. 1 receptor. Mol Pharmacol 60: 432-439.
3. 1 receptor. Mol Pharmacol 65: 426-436.
4. 1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol 53: 727-733.
5. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 403: 26-30.
6. Mills DC (1996) ADP receptors on platelets. Thromb Haemost 76: 835-856.
7. Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64: 1471-1483.
8. Surprenant A, North RA (2009) Signaling at purinergic P2X receptors. Annu Rev Physiol 71: 333-359.
9. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82: 1013-1067.
10. 4 ion channel in the closed state. Nature 460: 592-598.
11. 2 receptors identified by the substituted cysteine accessibility method. J Neurosci 18: 2350-2359.
12. Rassendren F, Buell G, Newbolt A, North RA, Surprenant A (1997) Identification of amino acid residues contributing to the pore of a P2X receptor. EMBO J 16: 3446-3454.
13. Nicke A, Baumert HG, Rettinger J, Eichele A, Lambrecht G, Mutschler E, Schmalzing G (1998) P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J 17: 3016-3028.
14. Browne LE, Jiang LH, North RA (2010) New structure enlivens interest in P2X receptors. Trends Pharmacol Sci 31: 229-237.
15. Young MT (2010) P2X receptors: dawn of the post-structure era. Trends Biochem Sci 35: 83-90.
16. Evans RJ (2010) Structural interpretation of P2X receptor mutagenesis studies on drug action. Br J Pharmacol 161: 961-971.
17. Lalo U, Pankratov Y, Wichert SP, Rossner MJ, North RA, Kirchhoff F, Verkhratsky A (2008) P2X1 and P2X5 subunits form the functional P2X receptor in mouse cortical astrocytes. J Neurosci 28: 5473-5480.
18. Torres GE, Haines WR, Egan TM, Voigt MM (1998) Co-expression of P2X1 and P2X5 receptor subunits reveals a novel ATP-gated ion channel. Mol Pharmacol 54: 989-993.
19. 1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression. J Biol Chem 273: 11544-11547.
20. Wang L, Ostberg O, Wihlborg AK, Brogren H, Jern S, Erlinge D (2003) Quantification of ADP and ATP receptor expression in human platelets. J Thromb Haemost 1: 330-336.
21. 1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors. Br J Pharmacol 135: 363-372.
22. Egan TM, Khakh BS (2004) Contribution of calcium ions to P2X channel responses. J Neurosci 24: 3413-3420.
23. Evans RJ, Lewis C, Virginio C, Lundstrom K, Buell G, Surprenant A, North RA (1996) Ionic permeability of, and divalent cation effects on, two ATP-gated cation channels (P2X receptors) expressed in mammalian cells. J Physiol 497: 413-422.
24. Benham CD, Tsien RW (1987) A novel receptor-operated Ca2+-permeable channel activated by ATP in smooth muscle. Nature 328: 275-278.
25. Benham CD (1989) ATP-activated channels gate calcium entry in single smooth muscle cells dissociated from rabbit ear artery. J Physiol 419: 689-701.
26. Mahaut-Smith MP, Martinez-Pinna J, Gurung IS (2008) A role for membrane potential in regulating GPCRs? Trends Pharmacol Sci 29: 421-429.
27. q-coupled receptors. J Biol Chem 280: 1490-1498.
28. 2X receptor for extracellular ATP. Nature 371: 516-519.
29. 2+ in the human platelet. J Thromb Haemost 5: 910-917.
30. 2T purinoceptors in human platelets. J Biol Chem 271: 2879-2881.
31. Mahaut-Smith MP, Sage SO, Rink TJ (1992) Rapid ADP-evoked currents in human platelets recorded with the nystatin permeabilized patch technique. J Biol Chem 267: 3060-3065.
32. 1 receptors does not involve direct channel phosphorylation. Biochem J 382: 101-110.
33. Ase AR, Raouf R, Belanger D, Hamel E, Seguela P (2005) Potentiation of P2X1 ATP-gated currents by 5-hydroxytryptamine 2A receptors involves diacylglycerol-dependent kinases and intracellular calcium. J Pharmacol Exp Ther 315: 144-154.
34. Wen H, Evans RJ (2009) Regions of the amino terminus of the P2X receptor required for modification by phorbol ester and mGluR1alpha receptors. J Neurochem 108: 331-340.
35. Vial C, Evans RJ (2005) Disruption of lipid rafts inhibits P2X1 receptor-mediated currents and arterial vasoconstriction. J Biol Chem 280: 30705-30711.
36. 1 receptors to disruption of lipid rafts. Biochem Biophys Res Commun 343: 415-419.
37. Lalo U, Allsopp RC, Mahaut-Smith MP, Evans RJ (2010) P2X1 receptor mobility and trafficking; regulation by receptor insertion and activation. J Neurochem 113: 1177-1187.
38. Rolf MG, Brearley CA, Mahaut-Smith MP (2001) Platelet shape change evoked by selective activation of P2X1 purinoceptors with α,β-Methylene ATP. Thromb Haemost 85: 303-308.
39. 1 receptors. J Thromb Haemost 1: 2626-2635.
40. 1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost 4: 882-890.
41. Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C (2005) Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4, 4′, 4″, 4‴-(carbonylbis(imino-5, 1, 3-benzenetriylbis-(carbonylimino)))t etrakis-benzene-1, 3-disulfonic acid octasodium salt]. J Pharmacol Exp Ther 314: 232-243.
42. 1 receptors in human platelets. Naunyn Schmiedebergs Arch Pharmacol 367(suppl 1): R35.
43. 1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 86: 1264-1271.
44. 1 receptors and human platelet function. PhD Thesis, University of Cambridge.
45. 2+-permeable cation channels in mouse, rat and guinea-pig megakaryocytes: a patch-clamp study. J Physiol 495: 339-352.
46. Cauwenberghs S, Feijge MA, Hageman G, Hoylaerts M, Akkerman JW, Curvers J, Heemskerk JW (2006) Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation. Transfusion 46: 1018-1028.
47. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R (2003) Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 1: 2497-2509.
48. Atkinson B, Dwyer K, Enjyoji K, Robson SC (2006) Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Blood Cells Mol Dis 36: 217-222.
49. 2+-calmodulin and myosin light chain kinase activation. J Biol Chem 279: 26266-26273.
50. North RA, Surprenant A (2000) Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 40: 563-580.
51. Horner S, Hildebrandt C, Menke K, Lambrecht G (2004) Pharmacological properties of the homomeric bivalent ligand CLII and its monomer, MRS2159, at native P2 receptor subtypes. Naunyn-Schmiedebergs Arch Pharmacol 369: R30.
52. Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, Nickel P, Schmalzing G, Lambrecht G (2001) NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol 364: 285-290.
53. Kim YC, Brown SG, Harden TK, Boyer JL, Dubyak G, King BF, Burnstock G, Jacobson KA (2001) Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem 44: 340-349.
54. 1 receptors in human platelets with potency in the low nanomolar range. Naunyn Schmiedebergs Arch Pharmacol 372: 1-13.
55. Hulsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F (2003) NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol 470: 1-7.
56. Kassack MU, Braun K, Ganso M, Ullmann H, Nickel P, Boing B, Muller G, Lambrecht G (2004) Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem 39: 345-357.
57. Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, Lambrecht G (2005) Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology 48: 461-468.
58. 1 receptors. Eur J Pharmacol 387: R19-R21.
59. Oury C, Daenens K, Hu H, Toth-Zsamboki E, Bryckaert M, Hoylaerts MF (2006) ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X. J Thromb Haemost 4: 443-452.
60. 1 receptor. Neuropharmacology 39: 2044-2053.
61. Munkonda MN, Kauffenstein G, Kukulski F, Levesque SA, Legendre C, Pelletier J, Lavoie EG, Lecka J, Sevigny J (2007) Inhibition of human and mouse plasma membrane bound NTPDases by P2 receptor antagonists. Biochem Pharmacol 74: 1524-1534.
62. Morrell CN, Sun H, Ikeda M, Beique JC, Swaim AM, Mason E, Martin TV, Thompson LE, Gozen O, Ampagoomian D, Sprengel R, Rothstein J, Faraday N, Huganir R, Lowenstein CJ (2008) Glutamate mediates platelet activation through the AMPA receptor. J Exp Med 205: 575-584.
63. Suzuki E, Kessler M, Montgomery K, Arai AC (2004) Divergent effects of the purinoceptor antagonists suramin and pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′, 8′-disulfonate) (PPNDS) on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Mol Pharmacol 66: 1738-1747.
64. 1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 131: 108-114.
65. 1-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 100: 2499-2505.
66. Cusack NJ, Hourani SM (1982) Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br J Pharmacol 76: 221-227.
67. 2T-purinoceptors on human blood platelets. Br J Pharmacol 108: 728-733.
68. Jin J, Daniel JL, Kunapuli SP (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273: 2030-2034.
69. Savi P, Bornia J, Salel V, Delfaud M, Herbert JM (1997) Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel. Br J Haematol 98: 880-886.
70. Takano S, Kimura J, Matsuoka I, Ono T (1999) No requirement of P2X1 purinoceptors for platelet aggregation. Eur J Pharmacol 372: 305-309.
71. 1 cation channel in thrombosis of small arteries in vivo. J Exp Med 198: 661-667.
72. 2+ influx on functional responses in human platelets. Thromb Haemost 88: 495-502.
73. 1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. J Biol Chem 278: 46661-46667.
74. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda KJ, Fratto CM, Tolley E, Kraiss LW, McIntyre TM, Zimmerman GA, Weyrich AS (2005) Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 122: 379-391.
75. 1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 101: 3969-3976.
76. 2+ responses of human platelets. Thromb Haemost 94: 37-40.
77. Woulfe D, Yang J, Prevost N, O'Brien P, Fortna R, Tognolini M, Jiang H, Wu J, Brass LF (2004) Signaling receptors on platelets and megakaryocytes. Methods Mol Biol 273: 3-32.
78. Grenegard M, Vretenbrant-Oberg K, Nylander M, Desilets S, Lindstrom EG, Larsson A, Ramstrom I, Ramstrom S, Lindahl TL (2008) The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine. J Biol Chem 283: 18493-18504.
79. 3 activation in platelets. J Biol Chem 277: 39493-39498.
80. Baurand A, Raboisson P, Freund M, Leon C, Cazenave JP, Bourguignon JJ, Gachet C (2001) Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 412: 213-221.
81. i-coupled receptors. J Thromb Haemost 8: 2273-2282.
82. i pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem 277: 47588-47595.
83. 1-deficient mice. Nat Med 5: 1199-1202.
84. 1 receptor-null mice. J Clin Invest 104: 1731-1737.
85. i signaling in the platelets of a patient with a chronic bleeding disorder. Blood 101: 4828-4835.
86. i2. J Clin Invest 108: 477-483.
87. z, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci USA 97: 9984-9989.
88. i family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 277: 46035-46042.
89. Kelleher KL, Matthaei KI, Hendry IA (2001) Targeted disruption of the mouse Gz-alpha gene: a role for Gz in platelet function? Thromb Haemost 85: 529-532.
90. Mahaut-Smith MP, Sage SO, Rink TJ (1990) Receptor-activated single channels in intact human platelets. J Biol Chem 265: 10479-10483.
91. Sage SO, Rink TJ (1987) The kinetics of changes in intracellular calcium concentration in fura-2-loaded human platelets. J Biol Chem 262: 16364-16369.
92. 2+ store. Biochem J 265: 675-680.
93. Sage SO, Rink TJ, Mahaut-Smith MP (1991) Resting and ADP-evoked changes in cytosolic free sodium concentration in human platelets loaded with the indicator SBFI. J Physiol 441: 559-573.
94. 1 receptors supports a role for ATP during hemostasis and thrombosis. Blood 102: 3646-3651.
95. Heptinstall S, Mulley GP (1977) Adenosine diphosphate induced platelet aggregation and release reaction in heparinized platelet rich plasma and the influence of added citrate. Br J Haematol 36: 565-571.
96. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D'Agostino RA, Levy D, Tofler GH (2001) Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 103: 3051-3056.
97. Semple JW, Freedman J (2010) Platelets and innate immunity. Cell Mol Life Sci 67: 499-511.
98. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O (2005) Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol 83: 196-198.
99. Shiraki R, Inoue N, Kawasaki S, Takei A, Kadotani M, Ohnishi Y, Ejiri J, Kobayashi S, Hirata K, Kawashima S, Yokoyama M (2004) Expression of Toll-like receptors on human platelets. Thromb Res 113: 379-385.
100. 2+ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation. Thromb Haemost 103: 398-407.
101. Trier DA, Gank KD, Kupferwasser D, Yount NY, French WJ, Michelson AD, Kupferwasser LI, Xiong YQ, Bayer AS, Yeaman MR (2008) Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect Immun 76: 5706-5713.
102. Jackson SP, Nesbitt WS, Westein E (2009) Dynamics of platelet thrombus formation. J Thromb Haemost 7(Suppl 1): 17-20.
103. Ruggeri ZM, Mendolicchio GL (2007) Adhesion mechanisms in platelet function. Circ Res 100: 1673-1685.
104. Moritz MW, Reimers RC, Baker RK, Sutera SP, Joist JH (1983) Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. J Lab Clin Med 101: 537-544.
105. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD (1988) Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71: 1366-1374.
106. Saba HI, Saba SR, Morelli GA (1984) Effect of heparin on platelet aggregation. Am J Hematol 17: 295-306.
107. Westwick J, Scully MF, Poll C, Kakkar VV (1986) Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 42: 435-447.
108. Mahaut-Smith MP, Rink TJ, Collins SC, Sage SO (1990) Voltage-gated potassium channels and the control of membrane potential in human platelets. J Physiol 428: 723-735.
109. Maruyama Y (1987) A patch-clamp study of mammalian platelets and their voltage-gated potassium current. J Physiol 391: 467-485.
110. 3(5) fluorescence and optical density. Thromb Haemost 54: 645-649.
111. 1 receptors in platelet activation. Platelets 15: 131-144.
112. Bauer M, Retzer M, Wilde JI, Maschberger P, Essler M, Aepfelbacher M, Watson SP, Siess W (1999) Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood 94: 1665-1672.
113. 13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 144: 745-754.
114. Paul BZ, Daniel JL, Kunapuli SP (1999) Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 274: 28293-28300.
115. Wilde JI, Retzer M, Siess W, Watson SP (2000) ADP-induced platelet shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation. Platelets 11: 286-295.
116. Kawa K (2004) Discrete but simultaneous release of adenine nucleotides and serotonin from mouse megakaryocytes as detected with patch- and carbon-fiber electrodes. Am J Physiol Cell Physiol 286: C119-C128.
117. 1 receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. Blood 106: 1644-1651.
118. Atkinson BT, Stafford MJ, Pears CJ, Watson SP (2001) Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin. Eur J Biochem 268: 5242-5248.
119. 2+ responses. Blood 90: 2615-2625.
120. Lu Q, Clemetson JM, Clemetson KJ (2005) Translocation of GPIb and Fc receptor gamma-chain to cytoskeleton in mucetin-activated platelets. J Thromb Haemost 3: 2065-2076.
121. Jackson SP, Nesbitt WS, Kulkarni S (2003) Signaling events underlying thrombus formation. J Thromb Haemost 1: 1602-1612.
122. Siess W (1989) Molecular mechanisms of platelet activation. Physiol Rev 69: 58-178.
123. Bergmeier W, Stefanini L (2009) Novel molecules in calcium signaling in platelets. J Thromb Haemost 7(Suppl 1): 187-190.
124. Kawasaki H, Springett GM, Toki S, Canales JJ, Harlan P, Blumenstiel JP, Chen EJ, Bany IA, Mochizuki N, Ashbacher A, Matsuda M, Housman DE, Graybiel AM (1998) A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci USA 95: 13278-13283.
125. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, Housman DE, Graybiel AM (2004) CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 10: 982-986.
126. Stefanini L, Roden RC, Bergmeier W (2009) CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood 114: 2506-2514.
127. Cifuni SM, Wagner DD, Bergmeier W (2008) CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood 112: 1696-1703.
128. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B (2004) Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 104: 3190-3197.
129. Furie BC, Furie B (2006) Tissue factor pathway vs. collagen pathway for in vivo platelet activation. Blood Cells Mol Dis 36: 135-138.
130. Hechler B, Nonne C, Eckly A, Magnenat S, Rinckel JY, Denis CV, Freund M, Cazenave JP, Lanza F, Gachet C (2010) Arterial thrombosis: relevance of a model with two levels of severity assessed by histological, ultrastructural and functional characterization. J Thromb Haemost 8: 173-84.
131. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJJ, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107: 1591-1598.
132. Bluestein D, Niu L, Schoephoerster RT, Dewanjee MK (1997) Fluid mechanics of arterial stenosis: relationship to the development of mural thrombus. Ann Biomed Eng 25: 344-356.
133. Siegel JM, Markou CP, Ku DN, Hanson SR (1994) A scaling law for wall shear rate through an arterial stenosis. J Biomech Eng 116: 446-451.
134. Mailhac A, Badimon JJ, Fallon JT, Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L (1994) Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 90: 988-996.
135. Cao L, Young MT, Broomhead HE, Fountain SJ, North RA (2007) Thr339-to-serine substitution in rat P2X2 receptor second transmembrane domain causes constitutive opening and indicates a gating role for Lys308. J Neurosci 27: 12916-12923.
136. Cao L, Broomhead HE, Young MT, North RA (2009) Polar residues in the second transmembrane domain of the rat P2X2 receptor that affect spontaneous gating, unitary conductance, and rectification. J Neurosci 29: 14257-14264.
137. Born GV, Kratzer MA (1984) Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man. J Physiol 354: 419-429.
138. Beigi R, Kobatake E, Aizawa M, Dubyak GR (1999) Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol 276: C267-C278.
139. Wan J, Ristenpart WD, Stone HA (2008) Dynamics of shear-induced ATP release from red blood cells. Proc Natl Acad Sci USA 105: 16432-16437.
140. Sprague RS, Stephenson AH, Ellsworth ML (2007) Red not dead: signaling in and from erythrocytes. Trends Endocrinol Metab 18: 350-355.
141. Macfarlane DE, Mills DC (1975) The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood 46: 309-320.
142. Cusack NJ, Hourani SM (1982) Competitive inhibition by adenosine 5′-triphosphate of the actions on human platelets of 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-methylthioadenosine 5′-diphosphate. Br J Pharmacol 77: 329-333.
143. Bianchi BR, Lynch KJ, Touma E, Niforatos W, Burgard EC, Alexander KM, Park HS, Yu H, Metzger R, Kowaluk E, Jarvis MF, van Biesen T (1999) Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 376: 127-138.
144. Cinkilic O, King BF, van der Giet M, Schluter H, Zidek W, Burnstock G (2001) Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety. J Pharmacol Exp Ther 299: 131-136.
145. 2X purinoceptors). Mol Pharmacol 48: 178-183.
146. nGs) on rat mesenteric artery P2X receptor ion channels. Br J Pharmacol 129: 124-130.
147. Sage SO, MacKenzie AB, Jenner S, Mahaut-Smith MP (1997) Purinoceptor-evoked calcium signalling in human platelets. Prostaglandins Leukot Essent Fatty Acids 57: 435-438.
148. Wildman SS, Brown SG, King BF, Burnstock G (1999) Selectivity of diadenosine polyphosphates for rat P2X receptor subunits. Eur J Pharmacol 367: 119-123.
149. Jankowski J, Potthoff W, van der Giet M, Tepel M, Zidek W, Schluter H (1999) High-performance liquid chromatographic assay of the diadenosine polyphosphates in human platelets. Anal Biochem 269: 72-78.
150. 7-Di(adenosine-5′)-heptaphosphate from human platelets. J Biol Chem 274: 23926-23931.
151. 2G in releasable granules of platelets. J Biol Chem 276: 8904-8909.
152. Lewis CJ, Evans RJ (2000) Lack of run-down of smooth muscle P2X receptor currents recorded with the amphotericin permeabilized patch technique, physiological and pharmacological characterization of the properties of mesenteric artery P2X receptor ion channels. Br J Pharmacol 131: 1659-1666.
153. 3A in whole blood. The dinucleotides are long-lived signal molecules in the blood ending up as intracellular ATP in the erythrocytes. Eur J Biochem 173: 241-245.
154. Schluter H, Tepel M, Zidek W (1996) Vascular actions of diadenosine phosphates. J Auton Pharmacol 16: 357-362.
155. Tolle M, Jankowski V, Schuchardt M, Wiedon A, Huang T, Hub F, Kowalska J, Jemielity J, Guranowski A, Loddenkemper C, Zidek W, Jankowski J, van der Giet M (2008) Adenosine 5′-tetraphosphate is a highly potent purinergic endothelium-derived vasoconstrictor. Circ Res 103: 1100-1108.
156. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J (2005) Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. Nat Med 11: 223-227.
157. Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL III (2010) Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res 125: 159-165.
158. 2X1 receptor is preferentially activated by adenosine diphosphate in platelets and megakaryocytic cells. Blood 98: 100-107.
159. 1 receptor: its activation by physiological agonists and potential as an antithrombotic target. PhD Thesis, University of Cambridge.
160. Geiger J, Nolte C, Butt E, Sage SO, Walter U (1992) Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci USA 89: 1031-1035.
161. 2TAC receptors in ADP-evoked calcium signalling in human platelets. Cell Calcium 28: 119-126.